ALDBY.PA $0.00 0%
ALUP11.SA $28.57 1.7088%
LGIH $117.36 -1.7332%
PRLH $10.49 0.0954%
SHOW3.SA $1.55 -2.5157%
AI $19.15 -3.4778%
0053.HK $64.00 0%
UTI $5.81 0.8681%
SNGX $0.76 -0.8831%
0NWC.L $197.27 -4.8951%
ISCB $45.38 -0.6622%
BOE.L $200.50 0%
ASCAR $0.15 0%
1865.HK $0.44 -1.1236%
ERTH $47.17 0.6674%
1008.HK $0.21 -1.4354%
CAT $208.49 -0.7356%
HALL $4.15 10.2819%
PROL.PA $0.29 0%
BGR $11.86 -0.5392%
SNSY3.SA $4.34 0%
IPU.L $427.00 1.9093%
0P00017UWP.L $15 749.60 0.2661%
PVL $2.56 -1.9157%
CCIV $24.25 0%
QRFT $38.55 0.3183%
KN.PA $4.00 0%
FLQE $23.82 -1.00599%
1150.HK $0.13 0%
JFJ.L $472.00 0.4255%
6100.HK $9.39 -0.6349%
HCAPZ $25.15 0%
DCRCU $14.79 0%
0HAL.L $106.65 0.9627%
ROST $103.42 0.8632%
RBT.PA $875.00 -0.2281%
DBD $0.33 -7.6349%
1845.HK $0.26 0%
AFGE $18.11 -0.7671%
PNFPP $21.35 -0.1403%
PLDR $22.94 -0.247%
LMACW $0.00 0%
NUVB $1.61 -0.3106%
IMTE $0.55 1.8519%
0P000147MF.L $9 422.87 -0.3528%
PEGRW $0.07 18.9744%
IPOS $15.96 1.5267%
DUST $9.91 0.101%
FXC $72.14 -0.5514%
AMPI $10.07 0%
WIZZ.L $3 009.00 1.041%
FSTA.L $534.00 0.7547%
OZK $31.39 0.1915%
LEE $12.06 -3.6741%
DHCAW $0.03 -38.8%
RHM.L $0.74 -0.3893%
BCSAU $10.48 0%
EWRE $30.22 -0.6898%
ACRL.L $34.70 0.289%
AMS $2.75 -1.7822%
ADMS $8.22 0%
MSOS $5.24 -1.2264%
PRUC.L $17.54 -0.0143%
ZAM.L $7.50 3.4483%
FEN $12.60 0.3984%
0436.HK $0.09 19.4445%
DD $63.36 -0.783%
MLBBO.PA $4.94 0%
MPWR $393.19 -1.3597%
KMR.L $448.00 -0.6652%
KFS $8.46 0.5945%
1572.HK $0.10 2%
XENT $28.24 0%
SWAN $25.45 -0.7023%
1259.HK $0.04 5.5556%
MLSEQ.PA $0.01 0%
RYAAY $98.89 -0.9118%
TRIN $11.40 -1.648%
SVML.L $22.50 0%
HOLUU $13.65 0%
MYT $2.16 0%
JMBS $46.45 -0.4498%
MTU.L $107.50 1.1765%
BCYPW $1.10 0%
AFARW $0.04 -6.1033%
1110.HK $0.77 8.4507%
XS8R.L $9 010.00 0.2225%
GTHX $2.70 -3.2258%
WNNR $10.54 0%
0HD2.L $207.89 -1.4879%
PANX.PA $35.70 -0.014%
LSAI.L $0.15 0%
HEXA.PA $19.60 0%
NZF $11.60 -0.489%
UIFS.L $724.13 0.1383%
MLOSA.PA $1.46 0%
INT $22.96 0.0436%
8366.HK $0.03 -3.0303%
MAIN $39.60 -0.8016%
HPK $14.18 -7.1382%
Eng
Логотип
Eng
Лого

Medivir AB (publ) 0GP7.L

$7.92

На 13:47, 16 марта 2023

Ранг: 2

Ранг - это оценка кредитоспособности корпорации.

Ключевые показатели

  • Marketcap

    2116765.00000000

  • week52high

    0.00

  • week52low

    0.00

  • Revenue

  • P/E TTM

    0

  • Beta

    0.35038100

  • EPS

    -1.58500000

  • Last Dividend

    0.28500000

  • Next Earnings Date

    07 мая 2023 г. в 03:51

Описание компании

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma. In addition, the company develops MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors. It has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

Свежие комментарии

Оставьте свой голос

Анонимное голосование

Будет ли рост российского рынка к концу года?

  • Да

    87%

  • Нет

    12%

Проголосовал 8 человек